Avelumab and Merkel Cell Carcinoma: Prognosis and Treatment Considerations

From General Health Awareness to Occupational Exposure

General health and science communication has long emphasized the importance of informed decision-making regarding medical treatments and their potential long-term consequences. In this tradition, public health messaging has focused on empowering individuals with knowledge about therapeutic options, including immune checkpoint inhibitors, which have revolutionized oncology. As these therapies become more widespread, the scope of health information must expand to address not only clinical outcomes but also the broader implications of exposure to such agents. Within this context, the transition from general health awareness to occupational exposure concern is both logical and necessary. Healthcare workers, pharmaceutical manufacturing staff, and others who handle or administer biologic therapies like avelumab may face unique, non-clinical exposure scenarios. While the primary focus of patient education remains on treatment efficacy and prognosis, the occupational setting introduces a distinct dimension: the need to understand potential risks associated with repeated, low-level contact with these substances. This pivot does not imply causality but rather underscores a precautionary principle—extending the legacy of health literacy to include workplace safety. Thus, the same rigor applied to patient counseling should inform protocols for those whose professional duties involve handling avelumab, ensuring that risk awareness is proportionate and evidence-informed.

Avelumab: Mechanism and Clinical Use in Merkel Cell Carcinoma

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It was approved in the United States, the European Union, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), making it the first therapeutic agent specifically approved for this indication, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). This approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Merkel cell carcinoma is a rare and aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and its incidence is increasing, with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Clinical presentation typically involves a rapidly growing, painless, firm, red or purple nodule on sun-exposed skin, often on the head, neck, or extremities. Diagnosis is confirmed by histopathology and immunohistochemistry, showing characteristic neuroendocrine markers such as cytokeratin 20 and chromogranin A. Despite advances in systemic therapy, approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors (ICIs) progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Avelumab's mechanism of action involves blocking PD-L1 on tumor cells and immune cells, thereby enhancing T-cell-mediated antitumor immune responses.

Immune-Related Adverse Events and Risk Considerations

Checkpoint inhibitors, including avelumab, are known to cause overactivation of the immune system, leading to immune-related adverse events (irAEs) (https://pubmed.ncbi.nlm.nih.gov/31543781/). Reported adverse effects include hypercalcaemia due to reactivation of sarcoidosis, as described in a case of a patient with metastatic MCC on avelumab, which was managed with corticosteroids to full resolution, allowing safe continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). Other irAEs may include dermatitis, colitis, hepatitis, pneumonitis, and endocrinopathies, though specific incidence rates for avelumab in MCC are not detailed in the provided evidence. The mechanistic pathways linking avelumab to MCC are primarily therapeutic rather than causative. Avelumab is used to treat MCC, not to cause it. However, the risk narrative must address the adequacy of warnings regarding avelumab and MCC. The evidence indicates that avelumab is approved for metastatic MCC, and its use is associated with a risk of irAEs, which are generally manageable. The timeline between exposure and documented harm is relevant for irAEs, which can occur weeks to months after initiation of therapy. For example, hypercalcaemia due to sarcoidosis reactivation was reported during treatment with avelumab for metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/31543781/). No evidence suggests a causal link between avelumab and the development of MCC; rather, avelumab is a treatment for existing MCC.

Prognosis and Treatment Options for Avelumab-Refractory Merkel Cell Carcinoma

Prognosis-related considerations for affected patients are critical. For patients with avelumab-refractory MCC, efficient and safe treatment options are limited. In Europe, approved systemic therapies are limited to the PD-L1 inhibitor avelumab (https://pubmed.ncbi.nlm.nih.gov/33439294/). For avelumab-refractory patients, combined ipilimumab plus nivolumab (IPI/NIVO) has shown activity. In a retrospective study at three German sites, three out of five patients with avelumab-refractory metastatic MCC responded to combined IPI/NIVO according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG reported that immune checkpoint inhibition has significantly improved treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, for patients who progress on avelumab, alternative therapies such as IPI/NIVO may offer benefit, though data are limited to small retrospective series. The timeline between avelumab exposure and documented harm primarily involves irAEs, which can occur during treatment. For patients who develop avelumab-refractory disease, the timeline for progression is variable, but approximately 50% of patients with advanced MCC treated with ICI progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). The prognosis for patients with avelumab-refractory MCC is poor, but salvage therapy with IPI/NIVO may provide responses in a subset of patients. In summary, avelumab is a key therapeutic agent for metastatic MCC, with a favorable risk-benefit profile when managed for irAEs. Adequate warnings should include the risk of irAEs, including rare events like sarcoidosis reactivation, and the potential for disease progression despite treatment. Prognosis for affected patients depends on response to avelumab and availability of subsequent therapies.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Community Resource & Benefit Desk

Request archival records or inquire about member-exclusive transition and benefit programs.

Frequently Asked Questions

What is avelumab and how does it work in Merkel cell carcinoma?

Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody that functions as an immune checkpoint inhibitor by targeting programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It is approved for the treatment of metastatic Merkel cell carcinoma (MCC) and works by blocking PD-L1 on tumor cells and immune cells, thereby enhancing T-cell-mediated antitumor immune responses.

What are the common immune-related adverse events associated with avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). These may include dermatitis, colitis, hepatitis, pneumonitis, endocrinopathies, and rare events like hypercalcaemia due to sarcoidosis reactivation. Most irAEs are manageable with corticosteroids and other supportive care.

What is the prognosis for patients with avelumab-refractory Merkel cell carcinoma?

The prognosis for patients with avelumab-refractory MCC is poor, but salvage therapy with combined ipilimumab plus nivolumab (IPI/NIVO) has shown activity in a subset of patients (https://pubmed.ncbi.nlm.nih.gov/33439294/). Approximately 50% of patients with advanced MCC treated with immune checkpoint inhibitors progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Check Whether Your Situation Qualifies

Free and confidential. No obligation — an initial records screening only.

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.